Peptides for cancer support: the immune modulation approach

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

In 2022, nearly 20.0 million new cancer cases were reported globally, highlighting the persistent challenge of this disease [2].. While conventional treatments like chemotherapy and radiation remain foundational, they often carry significant side effects, prompting a search for adjunctive therapies that can bolster the body’s natural defenses.

In 2022, nearly 20.0 million new cancer cases were reported globally, highlighting the persistent challenge of this disease [2]. While conventional treatments like chemotherapy and radiation remain foundational, they often carry significant side effects, prompting a search for adjunctive therapies that can bolster the body’s natural defenses. Peptides, with their inherent ability to modulate immune responses, are emerging as promising candidates in cancer support, particularly through immune modulation.

Understanding Immune Modulation in Cancer

Cancer’s complexity often stems from its ability to evade or suppress the immune system. Tumors create an immunosuppressive microenvironment, hindering the body’s capacity to recognize and eliminate malignant cells. Immune modulation aims to re-educate or enhance immune cells to effectively target and destroy cancer, often reducing the harshness of traditional treatments.

Thymosin Alpha-1: A Key Immunomodulator

Thymosin alpha-1 (Ta1), a naturally occurring thymic peptide, has been recognized for its capacity to enhance and restore immune function [3]. It’s been utilized in various immunocompromised states and malignancies, acting as a potent enhancer of vaccine responses and a means to mitigate morbidity in infections. Ta1 primarily functions by:

Clinically, Ta1 is often administered subcutaneously. A common protocol involves 1.6 mg injected twice weekly for 6-12 months, particularly in conditions like hepatitis B and C, or as an adjunct in certain cancers [4]. For broader immune support, a general dosage of 1.5 mg subcutaneously every third day might be considered, with treatment durations varying from weeks for acute infections to several months for chronic conditions or cancer support [4].

Anticancer Peptides (ACPs): Direct and Indirect Immune Effects

Anticancer peptides (ACPs) represent a diverse group of molecules that can directly target cancer cells, inducing apoptosis or disrupting cell membranes, often with low toxicity to healthy cells [1]. Beyond direct cytotoxicity, many ACPs also exert immunomodulatory effects, contributing to the overall anti-tumor response. For instance, some peptides can inhibit angiogenesis, starving tumors of blood supply, while others can enhance the immune system's ability to recognize tumor-specific antigens [1].

Research by Sood et al. (2024) highlights ACPs' potential to overcome challenges like treatment resistance and tumor heterogeneity, which often plague conventional therapies [1]. These peptides can be synthetically created, offering a new therapeutic avenue.

The Nuance of Peptide Therapy in Cancer

While peptides like Ta1 show significant promise, it's crucial to understand the nuances. Ta1 has a favorable toxicity profile, with over 3,000 individuals treated in more than 70 clinical studies showing minimal side effects, primarily injection site reactions [4]. This contrasts sharply with major immune response modulators like interferon (IFN) and interleukin-2 (IL-2), which frequently cause flu-like symptoms, malaise, and even pulmonary edema [4].

However, the application of other peptides, such as BPC-157, in cancer contexts requires extreme caution. While BPC-157 demonstrates regenerative and cytoprotective effects in preclinical studies, its pro-angiogenic properties and activation of pathways like FAK–paxillin, which are implicated in tumor growth and metastasis, raise concerns [McGuire, 2025; Prisk, 2025]. A 2025 pharmaceutical review noted that BPC-157 increases VEGFR2 expression, a key receptor for vascular growth, and warned that it could inadvertently support tumor growth if cancer cells are present [Prisk, 2025]. Therefore, while some peptides enhance immune function against cancer, others might pose theoretical risks, necessitating careful consideration and further research.

Future Directions and Clinical Takeaway

The field of peptide-based immunotherapy is rapidly evolving. Researchers are exploring peptide inhibitors that selectively target immune checkpoints, similar to antibody-based immunotherapies but with potentially fewer side effects due to their smaller size and improved tumor penetration [Sui et al., 2023]. For example, novel D-peptides are being developed to block interactions like PD-1/PD-L1 and TIGIT/PVR, aiming to unleash T-cell activity against tumors [Sui et al., 2023].

A specific, actionable clinical takeaway for practitioners is to consider Thymosin Alpha-1 at a dose of 1.6 mg subcutaneously twice weekly as an immune-supportive adjunct in cancer patients, particularly those with compromised immune function or undergoing conventional therapies, given its established safety profile and broad immunomodulatory effects. Always assess for existing tumor burden and individual patient risk factors before initiating any peptide therapy, especially those with pro-angiogenic potential.

References